Display options
Cite
Brown PD. Matrix metalloproteinase inhibitors. Angiogenesis. 1998;1(2):142-54doi: 10.1023/A:1018373520193.
Brown, P. D. (1998). Matrix metalloproteinase inhibitors. Angiogenesis, 1(2), 142-54. https://doi.org/10.1023/A:1018373520193
Brown, P D. "Matrix metalloproteinase inhibitors." Angiogenesis vol. 1,2 (1998): 142-54. doi: https://doi.org/10.1023/A:1018373520193
Brown PD. Matrix metalloproteinase inhibitors. Angiogenesis. 1998;1(2):142-54. doi: 10.1023/A:1018373520193. PMID: 14517381.
Copy Download .nbib Format: NLM
Share it on

Angiogenesis. 1998;1(2):142-54. doi: 10.1023/A:1018373520193.

Matrix metalloproteinase inhibitors.

Angiogenesis

P D Brown

Affiliations

  1. Department of Clinical Research, British Biotech Pharmaceuticals Ltd, Oxford OX4 5LY, UK.

PMID: 14517381 DOI: 10.1023/A:1018373520193

Abstract

Matrix metalloproteinases (MMPs) are a family of structurally related enzymes that are capable of degrading a wide variety of extracellular matrix proteins. In addition to the role played by these enzymes in normal tissue remodeling, MMPs have been implicted in the pathogenesis of diseases such as rheumatoid arthritis and multiple sclerosis. In cancer increased MMP activity may facilitate tumor invasion, metastasis and tumor angiogenesis. Expression of high levels of MMPs in certain malignancies has been shown to be associated with a poor prognosis. Using structure-based design, a range of low molecular weight synthetic MMP inhibitors have been developed. These have proven effective in animal models of disease and several (CGS 27023A, AG3340, Ro 32-3555 and marimastat) have now commenced clinical trials.

Publication Types